Compare Hasbro, Inc. (HAS) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hasbro, Inc. vs State Street SPDR S&P Biotech ETF — how do they compare? Hasbro, Inc. trades at $93.38 (market cap $13.05B), while State Street SPDR S&P Biotech ETF trades at $153.62 (market cap $10.11B). The key difference: Hasbro, Inc. is the larger of the two by market cap, and Hasbro, Inc. pays a 3.03% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hasbro, Inc. for 97 Days and State Street SPDR S&P Biotech ETF for 38 Days on average.
| HAS | XBI | |
|---|---|---|
Market Cap | $13.05B | $10.11B |
Volume | 1,207,655 | 12,903,266 |
Sector | Consumer Cyclical | Broad Market / Factor |
52-Week High | $105.88 | $169.55 |
52-Week Low | $70.95 | $104.99 |
Typical Hold Time | 97 Days | 38 Days |
Enterprise Value | $15.24B | — |
Dividend Yield | 3.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hasbro (HAS) trades at $94.22, up 3.82% today, showing strong momentum after recent earnings beats. The stock maintains a bullish technical stance with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, the company demonstrates robust profitability with 64.41% gross margins and impressive ROE of 167.83%, despite a net loss in 2025. Analyst consensus remains positive with 51.52% buy ratings and a $107.60 price target, representing 14% upside potential from current levels.
Investment outlook appears favorable with strong gaming segment growth and cost-saving initiatives driving projected 2026 net income of $794 million. Key risks include high debt levels at 59.09% debt-to-asset ratio and competitive pressures in the toy industry. The upcoming Q3 2026 earnings report on October 20 will be crucial for validating the company's turnaround trajectory and growth projections.
XBI trades at $153.84, up 2.4% today, but technical indicators signal a bearish trend with resistance at $154. The ETF's modified equal-weight structure offers broad biotech exposure, benefiting from M&A activity and positive clinical catalysts, though key financial ratios are unavailable. Recent news highlights sector optimism driven by cancer vaccine breakthroughs and improved capital access.
Outlook is mixed: bullish sentiment from innovation and M&A supports growth potential, but high volatility and expense ratios relative to peers pose risks. Analyst consensus is neutral (100% Hold), suggesting cautious optimism amid technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hasbro, Inc.
Hasbro is a branded play company providing children and families around the world with entertainment offerings based on a world-class brand portfolio. From toys and games to television programming, motion pictures, and a licensing program, Hasbro reaches customers by leveraging its well-known brands such as Transformers, Nerf, and Magic: The Gathering. Ownership stakes in Discovery Family, which offers programming around Hasbro brands, and owned production capabilities from Entertainment One help bolster Hasbro's multichannel presence. The firm acquired Entertainment One in 2019, bolting on popular properties like Peppa Pig and PJ Masks, and has plans to tie up with Dungeons & Dragons Beyond in 2022, offering the firm access 10 million digital tabletop players.
Read more on HAS →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
